DESC:FIELD OF THE INVENTION
[001] The present invention relates to the field of cancer screening in medical science. More specifically, it relates to the development of a urinal, for performing spot analysis.

BACKGROUND FOR THE INVENTION:
[002] The following discussion of the background of the invention is intended to facilitate an understanding of the present invention. However, it should be appreciated that the discussion is not an acknowledgment or admission that any of the material referred to was published, known, or part of the common general knowledge in any jurisdiction as of the priority date of the application. The details provided herein the background if belongs to any publication is taken only as a reference for describing the problems, in general terminologies or principles or both of science and technology in the associated prior art.
[003] Cancer has now acquired the second and fourth ranks of the leading cause of adult death in urban and rural India, respectively. In India, the incidence of all types of cancers in the year 2020 was 1324413 out of which urinary system cancers (prostate, bladder, kidney, penis, and testis) constituted 87,855 or 6.63 %.2 Medical expenses for cancer treatment in India have increased drastically over the years which is quite distressing financially before death.
[004] Research studies have detected cell-free DNA specific to the bladder, malignant renal, and prostate in the urine of patients with urogenital cancers. Besides few studies have reported significantly higher total concentrations of urine cell-free DNA in bladder cancer patients than in healthy and benign patients.
[005] An Australian prior art patent document 2,019,232,890 B2 directed to a system and method for analyzing biological samples, such as dried human blood serum, to determine a disease state such as colorectal cancer (CRC). Using dried samples may hold the potential for enhancing localized concentration and/or segmentation of sample components. The method may comprise illuminating at least one location of a biological sample to generate a plurality of interacted photons, collecting the interacted photons, and generating at least one Raman data set representative of the biological sample. A system may comprise an illumination source to illuminate at least one location of a biological sample and generate at least one plurality of interacted photons, and at least one mirror for directing the interacted photons to a detector. The detector may be configured to generate at least one Raman data set representative of the biological sample. The system and method may utilize a FAST device for multipoint analysis or may be configured to analyze a sample using a line scanning configuration.
[006] In light of the foregoing, there is a need for a urinal prototype for cancer screening by quantitation of native nucleic acids in urine using UV spectroscopy that overcomes problems prevalent in the prior art.
[007] The information disclosed in this background of the disclosure section is only for the enhancement of understanding of the general background of the invention and should not be taken as an acknowledgment or any form of suggestion that this information forms the prior art already known to a person skilled in the art.

OBJECTS OF THE INVENTION:
[008] Some of the objects of the present disclosure, which at least one embodiment herein satisfies, are as follows.
[009] The principal object of the present invention is to overcome the disadvantages of the prior art by providing a urinal prototype for cancer screening by quantitation of native nucleic acids in urine using UV spectroscopy.
[010] An object of the present invention is to provide for a urinal prototype for cancer screening by quantitation of native nucleic acids in urine using UV spectroscopy that performs spot analysis for screening of urogenital cancers.
[011] Another object of the present invention is to provide a urinal prototype for cancer screening by quantitation of native nucleic acids in urine using UV spectroscopy that aims to develop a urinal prototype where screening for cancer will become part of daily life and get tied to the natural call of a subject for early detection of cancer which may reduce disease mortality by identifying premalignant and malignant tumors at an early stage of development when treatment may be more effective.
[012] Another object of the present invention is to provide a urinal prototype for cancer screening by quantitation of native nucleic acids in urine using UV spectroscopy, wherein results serve as a wakeup call for the subject and early detection to follow-up further with a clinical consultation for a thorough checkup.
[013] Another object of the present invention is to provide a urinal prototype for cancer screening by quantitation of native nucleic acids in urine using UV spectroscopy, wherein the urinals are easily deployed in the community and the health benefits can reach the population.
[014] Yet another object of the present invention is to provide a urinal prototype for cancer screening by quantitation of native nucleic acids in urine using UV spectroscopy, wherein the screening test is inexpensive, sensitive, and specific.
[015] Other objects and advantages of the present disclosure will be more apparent from the following description, which is not intended to limit the scope of the present disclosure.

SUMMARY OF THE INVENTION:
[016] Screening tests are limited by feasibility, cost-effectiveness, and the potential harms of invasive tests. Urinary system cancers are a potential candidate for screening because of their prevalence and significance. This study proposes to develop a proof of concept for a screening test that is inexpensive, sensitive, and specific which is very important for our country if we need to take it to the masses. A urinal is developed which does a spot analysis of the native urine nucleic acids by UV spectroscopy and communicate the results to the subject a few minutes after the natural call. The results serve as a wake-up call for the subject to follow up further with a clinical consultation as required. These urinals can be easily deployed at the community level and the health benefits can reach the masses.
[017] In one aspect of the present invention, the urinal prototype for cancer screening by quantitation of native nucleic acids in urine using UV spectroscopy is provided. The screening includes an initial step of obtaining a urine sample in a non-invasive manner.
[018] At next step, Nucleic acids (DNA or RNA) that contain conjugated double bonds in their purine and pyrimidine rings that have a maximum absorption peak at 260 nm are inspected.
[019] At next step, the intensity of the absorbance which is proportional to the concentration of nucleic acid according to the Lambert-Beer law is checked.
[020] At next step, the nucleic acid in the native urine sample is measured without any additional chemicals or processing.
[021] At next step, the screening tests are deployed for population screening in the future.
[022] In another aspect of the present invention, the urinal does a spot analysis of the native urine nucleic acids by UV spectroscopy and communicates the results to the subject a few minutes after the natural call.
[023] In another aspect of the present invention, the results serve as a wake-up call for the subject to follow up with a clinical consultation as required.
[024] In another aspect of the present invention, urinary system cancers are a potential candidate for screening because of their prevalence and significance.

BRIEF DESCRIPTION OF DRAWINGS:
[025] Reference will be made to embodiments of the invention, examples of which may be illustrated in accompanying figures. These figures are intended to be illustrative, not limiting. Although the invention is generally described in the context of these embodiments, it should be understood that it is not intended to limit the scope of the invention to these particular embodiments.
[026] No figures are attached.

DETAILED DESCRIPTION OF DRAWINGS:
[027] While the present invention is described herein by way of example using embodiments and illustrative drawings, those skilled in the art will recognize that the invention is not limited to the embodiments of drawing or drawings described and are not intended to represent the scale of the various components. Further, some components that may form a part of the invention may not be illustrated in certain figures, for ease of illustration, and such omissions do not limit the embodiments outlined in any way. It should be understood that the drawings and the detailed description thereto are not intended to limit the invention to the particular form disclosed, but on the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the scope of the present invention as defined by the appended claim.
[028] As used throughout this description, the word "may" is used in a permissive sense (i.e. meaning having the potential to), rather than the mandatory sense, (i.e. meaning must). Further, the words "a" or "an" mean "at least one” and the word “plurality” means “one or more” unless otherwise mentioned. Furthermore, the terminology and phraseology used herein are solely used for descriptive purposes and should not be construed as limiting in scope. Language such as "including," "comprising," "having," "containing," or "involving," and variations thereof, is intended to be broad and encompass the subject matter listed thereafter, equivalents, and additional subject matter not recited, and is not intended to exclude other additives, components, integers, or steps. Likewise, the term "comprising" is considered synonymous with the terms "including" or "containing" for applicable legal purposes. Any discussion of documents, acts, materials, devices, articles, and the like are included in the specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention.
[029] In this disclosure, whenever a composition or an element or a group of elements is preceded with the transitional phrase “comprising”, it is understood that we also contemplate the same composition, element, or group of elements with transitional phrases “consisting of”, “consisting”, “selected from the group of consisting of, “including”, or “is” preceding the recitation of the composition, element or group of elements and vice versa.
[030] The present invention is described hereinafter by various embodiments with reference to the accompanying drawing, wherein reference numerals used in the accompanying drawing correspond to the like elements throughout the description. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiment set forth herein. Rather, the embodiment is provided so that this disclosure will be thorough and complete and will fully convey the scope of the invention to those skilled in the art. In the following detailed description, numeric values and ranges are provided for various aspects of the implementations described. These values and ranges are to be treated as examples only and are not intended to limit the scope of the claims. In addition, several materials are identified as suitable for various facets of the implementations. These materials are to be treated as exemplary and are not intended to limit the scope of the invention.
[031] The present invention relates to a urinal that is developed to do a spot analysis of the native urine nucleic acids by UV spectroscopy and communicate the results to the subject a few minutes after the natural call. The results serve a as wake-up call for the subject to follow up further with a clinical consultation as required. These urinals can be easily deployed at the community level and the health benefits can reach the masses.
[032] A urine sample can be easily obtained in a non-invasive manner and is very convenient for the subject. Nucleic acids (DNA or RNA) contain conjugated double bonds in their purine and pyrimidine rings that have a maximum absorption peak at 260 nm. The intensity of this absorbance is proportional to the concentration of nucleic acid according to the Lambert-Beer law. The nucleic acid in the native urine sample can be measured very easily without any additional chemicals or processing which will make the test inexpensive. These characteristics make it quite feasible to deploy this screening test for population screening in the future.
[033] Screening tests are limited by feasibility, cost-effectiveness, and the potential harms of invasive tests. Urinary system cancers are a potential candidate for screening because of their prevalence and significance. This study proposes to develop a proof of concept for a screening test that is inexpensive, sensitive, and specific which is very important for our country if we need to take it to the masses. A urinal is developed which does a spot analysis of the native urine nucleic acids by UV spectroscopy and communicate the results to the subject a few minutes after the natural call. The results serve as a wake-up call for the subject to follow up further with a clinical consultation as required. These urinals can be easily deployed at the community level and the health benefits can reach the masses.
[034] In one aspect of the present invention, the urinal prototype for cancer screening by quantitation of native nucleic acids in urine using UV spectroscopy is provided. The screening includes an initial step of obtaining a urine sample in a non-invasive manner.
[035] At next step, Nucleic acids (DNA or RNA) that contain conjugated double bonds in their purine and pyrimidine rings that have a maximum absorption peak at 260 nm are inspected.
[036] At next step, the intensity of the absorbance which is proportional to the concentration of nucleic acid according to the Lambert-Beer law is checked.
[037] At next step, the nucleic acid in the native urine sample is measured without any additional chemicals or processing.
[038] At next step, the screening tests are deployed for population screening in the future.
[039] In another aspect of the present invention, the urinal does a spot analysis of the native urine nucleic acids by UV spectroscopy and communicates the results to the subject a few minutes after the natural call.
[040] In another aspect of the present invention, the results serve as a wake-up call for the subject to follow up with a clinical consultation as required.
[041] In another aspect of the present invention, urinary system cancers are a potential candidate for screening because of their prevalence and significance.
[042] The disclosure has been described with reference to the accompanying embodiments herein and the various features and advantageous details thereof are explained with reference to the non-limiting embodiments in the following description. Descriptions of well-known components and processing techniques are omitted so as to not unnecessarily obscure the embodiments herein.
[043] The foregoing description of the specific embodiments so fully revealed the general nature of the embodiments herein that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. Therefore, while the embodiments herein have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the scope of the embodiments as described herein.
,CLAIMS:We Claim:

1) A urinal prototype for cancer screening by quantitation of native nucleic acids in urine using UV spectroscopy, the screening comprises steps of:
- obtaining a urine sample in a non-invasive manner;
- inspecting Nucleic acids (DNA or RNA) that contain conjugated double bonds in their purine and pyrimidine rings that have a maximum absorption peak at 260 nm;
- checking the intensity of this absorbance which is proportional to the concentration of nucleic acid according to the Lambert-Beer law;
- measuring the nucleic acid in the native urine sample without any additional chemicals or processing; and
- deploying screening tests for population screening in the future.
2) The screening as claimed in claim 1, wherein the urinal does a spot analysis of the native urine nucleic acids by UV spectroscopy and communicates the results to the subject a few minutes after the natural call.
3) The screening as claimed in claim 1, wherein the results serve as a wake-up call for the subject to follow up with a clinical consultation as required.
4) The screening as claimed in claim 1, wherein the urinary system cancers are a potential candidate for screening because of their prevalence and significance.